Mullaney D T, John J F
Antimicrob Agents Chemother. 1982 Mar;21(3):421-5. doi: 10.1128/AAC.21.3.421.
We evaluated the efficacy, safety, and tolerance of cefotaxime in 35 adults (25 with pleuropulmonary infections, 7 with genitourinary tract infections, and 3 with soft tissue infections). Of these 35 patients, 18 (51.4%) were seriously or critically ill. In vitro susceptibility testing revealed that 90.4% of the pathogens isolated were susceptible to cefotaxime (minimal inhibitory concentration, less than 8 micrograms/ml), 4.8% were intermediately susceptible (minimal inhibitory concentration, 8 to 32 micrograms/ml), and 4.8% were resistant (minimal inhibitory concentration, greater than 32 micrograms/ml). A total of 34 of the 35 patients (97%) were clinically and bacteriologically cured of their infections. Adverse reactions occurred in two patients, but these reactions did not require interruption of therapy.
我们评估了头孢噻肟对35例成人患者（25例胸膜肺部感染、7例泌尿生殖道感染和3例软组织感染）的疗效、安全性及耐受性。这35例患者中，18例（51.4%）病情严重或危急。体外药敏试验显示，分离出的病原体中有90.4%对头孢噻肟敏感（最低抑菌浓度小于8微克/毫升），4.8%为中度敏感（最低抑菌浓度为8至32微克/毫升），4.8%耐药（最低抑菌浓度大于32微克/毫升）。35例患者中有34例（97%）感染在临床和细菌学上得到治愈。两名患者出现不良反应，但这些反应无需中断治疗。
